18 and older, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Meeting Retention in HIV Medical Care Guidelines at 52 WeeksPrimary· 52 weeks
Objective data from participants' electronic health records will be obtained to examine how many medical appointments they attended in the past year at their HIV treatment clinic. Participants will be deemed as sufficiently retained if they attend at least 3 medical visits during this period.
Group
Value
95% CI
Acceptance-Based Behavior Therapy (ABBT)
20
Enhanced-Treatment-as-Usual (ETAU)
16
Number of Participants Who Met HIV Virologic SuppressionPrimary· 52 weeks
Objective data from participants' electronic health records will be obtained to examine their viral load, which is a blood-based measure of the amount of HIV viruses in the person's body. If participants are not currently retained in medical care and blood sample results are not available in their electronic health record, they will submit 1-3ml of blood at each assessment through the study's research phlebotomist. A viral load that measures as "undetectable" (i.e., fewer than 200 copies of HIV per millilitre of blood) will represent virologic suppression, which is a positive indication of HIV
Self-report data of participants' HIV antiretroviral treatment adherence will be obtained with the SRSI. Scores range from 0 to 5, which correspond to "very poor" to "excellent" medication adherence.
Group
Value
95% CI
Acceptance-Based Behavior Therapy (ABBT)
4.5
± 0.7
Enhanced-Treatment-as-Usual (ETAU)
4.6
± 0.7
Brief HIV Disclosure Scale (BHD)Secondary· 52 weeks
The BHD HIV disclosure scale will be used to assess for willingness to make informed disclosure and for actual disclosure of HIV status. Scores range from 8-32, with higher scores indicating increased willingness to disclose.
Group
Value
95% CI
Acceptance-Based Behavior Therapy (ABBT)
21.3
± 3.2
Enhanced-Treatment-as-Usual (ETAU)
22.1
± 4.2
The Multidimensional Scale of Perceived Social Support (MSPSS)Secondary· 52 weeks
The MSPSS will be used to measure perceived social support. Scores range from 1-84, with higher scores indicating greater perceived social support.
Group
Value
95% CI
Acceptance-Based Behavior Therapy (ABBT)
5.8
± 0.7
Enhanced-Treatment-as-Usual (ETAU)
5.3
± 0.9
HIV Stigma Scale (HSS)Secondary· 52 weeks
The HSS will be used to measure self-reported experiences, fear, and perception of stigmatization due to being HIV+. Scores range from 6-24, with lower scores indicating less fear or concern about stigmatization.
Group
Value
95% CI
Acceptance-Based Behavior Therapy (ABBT)
19.5
± 4.5
Enhanced-Treatment-as-Usual (ETAU)
21.1
± 5.0
Sponsor's own description
The overall aim of this program of research is to test a newly developed intervention, Acceptance-Based Behavior Therapy (ABBT), to improve HIV patients' commitment to medical care.
The purpose of the proposed project is to establish the efficacy of ABBT and examine its mechanisms of action. To achieve the specific aims, the investigators will conduct a randomized clinical trial (n = 270), with two treatment arms: ABBT vs. an attention-matched HIV education control condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Other trials of Acceptance-Based Behavior Therapy (ABBT)
Trials testing the same drug.
NCT05540067 — Improving Mental Health Among the LGBTQ+ Community
· Phase 2
· active not recruiting
Other recruiting trials for HIV/AIDS
Currently open trials in the same condition.
NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
· NA
· recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study
· NA
· recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing
· NA
· recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents
· NA
· recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru
· NA
· active not recruiting
Other Brown University trials
Trials by the same sponsor.
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g
· Phase 2
· not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption
· Phase 2
· recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults
· NA
· recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
· Phase 4
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 14 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04201288.